GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Cash-to-Debt

ANL (Adlai Nortye) Cash-to-Debt : 2.48 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Adlai Nortye's cash to debt ratio for the quarter that ended in Jun. 2024 was 2.48.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Adlai Nortye could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Adlai Nortye's Cash-to-Debt or its related term are showing as below:

ANL' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.48   Med: 4.02   Max: 9.79
Current: 2.48

During the past 3 years, Adlai Nortye's highest Cash to Debt Ratio was 9.79. The lowest was 2.48. And the median was 4.02.

ANL's Cash-to-Debt is ranked worse than
63.62% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs ANL: 2.48

Adlai Nortye Cash-to-Debt Historical Data

The historical data trend for Adlai Nortye's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Adlai Nortye Cash-to-Debt Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Cash-to-Debt
8.84 9.79 3.12

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Cash-to-Debt Get a 7-Day Free Trial 9.79 4.91 2.84 3.12 2.48

Competitive Comparison of Adlai Nortye's Cash-to-Debt

For the Biotechnology subindustry, Adlai Nortye's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Cash-to-Debt falls into.


Adlai Nortye Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Adlai Nortye's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=98.499 / (31.079 + 0.469)
=3.12

Adlai Nortye's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=97.987 / (39.528 + 0)
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye  (NAS:ANL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Adlai Nortye Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Cash-to-Debt
Comparable Companies
MGTX KALV JANX AVTE ABUS VYGR BLUE AGEN FUSN CRBU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N2U0:Germany
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.